OccamzRazor, a New York-based company creating curative treatments for complex brain-aging diseases, such as Parkinson’s disease, raised $6.1M in funding.
The round was led by Jeff Dean, with participation from Lauder Partners, re.Mind Capital, and Valor Equity Partners.
The company intends to use the funds to launch their AI-enabled discovery pipeline and advance preclinical development in Parkinson’s.
Led by CEO Katharina Sophia Volz, OccamzRazor is on a mission to create curative treatments for complex brain-aging diseases, such as Parkinson’s disease by combining graph machine learning (RazorBrain™), graph prediction (RazorLink™), and natural language processing (RazorPanorama™), to generate testable data-driven hypotheses.
The company is headquartered at Johnson & Johnson’s innovation hub J-LABS in New York City.